SANA

Sana Biotechnology, Inc.

• Reuters·03/27 20:17

  Sana Biotechnology files Form 3; EVP and Chief Scientific Officer Dhavalkumar Dhirajlal Patel reports 99,510 common shares owned directly

• NASDAQ·03/20 14:13

  Weekly Buzz: GSK's Lynavoy Gets FDA Nod; Reproxalap Rejected Again; LNSR Ends Merger Deal

• TipRanks·03/13 16:45

  Durable HIP Technology Data De‑Risks Sana Biotechnology’s SC451 Program and Supports Buy Rating

• Dow Jones·03/13 16:22

  Sana Biotechnology Gains on Positive Results for Type 1 Diabetes Study

• NASDAQ·03/13 14:52

  Sana Biotechnology Reports Continued Positive 14-Month Results In Type 1 Diabetes Cell-Therapy Study

• Reuters·03/13 13:15

  BUZZ-Sana Biotechnology rises as cell transplant shows promise in type 1 diabetes treatment

• TipRanks·03/13 13:10

  Sana announces follow-up results from first-in-human study transplanting UP421

• Reuters·03/13 13:05

  Sana reports positive 14-month results from UP421 hypoimmune islet transplant study in type 1 diabetes

• Benzinga·03/13 13:03

  Sana Biotechnology Announces 14-Month Follow-Up Results From Investigator-Sponsored, First-In-Human Study Transplanting UP421 Into Patient With Type 1 Diabetes Without Any Immunosuppression

• Reuters·03/13 13:00

  SANA BIOTECHNOLOGY INC - NO SAFETY ISSUES IDENTIFIED IN UP421 ISLET CELL STUDY

• TipRanks·03/11 12:50

  Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Rapport Therapeutics, Inc. (RAPP)

• Simply Wall St·03/07 17:25

  Sana Diabetes Data And Funding Moves Reframe Risk For NasdaqGS SANA Investors

• TipRanks·03/06 17:45

  Sana Biotechnology: Advancing T1D and In Vivo CAR-T Programs with 2026 Catalysts and Solid Cash Runway Supporting Buy Rating

• TipRanks·03/05 10:40

  Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN) and Sana Biotechnology (SANA)

• TipRanks·03/05 06:02

  AI Adoption Exposes Sana Biotechnology to Rising Data, Compliance, and Reputational Risks